Tirzepatide

Tirzepatide is a once-weekly injectable peptide engineered from the gut hormone GIP to activate two incretin receptors at once: GIP and GLP-1 ³¹. In clinical research it produces some of the largest weight reductions reported for an incretin-based therapy, and it also lowers blood glucose in type 2 diabetes ³. It is sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea with obesity ³⁰. Major guidelines now place tirzepatide among first-line medication options for adults with obesity ⁴.

Tirzepatide is a synthetic 39-amino-acid peptide with a fatty-acid side chain that lets it bind albumin, giving it a half-life of about 5 days and once-weekly dosing ³¹. It works as a "twincretin" by activating both GIP and GLP-1 receptors ³¹.

Primary actions

• Insulin release only when glucose is high: both receptor arms signal the pancreas to release insulin in a glucose-dependent way, which reduces hypoglycemia risk ³¹.
• Less liver glucose output: modeling of trial data suggests tirzepatide lowers fasting glucose largely by suppressing liver glucose production independent of insulin ⁴⁰.
• Slowed stomach emptying and satiety: GLP-1 signaling delays gastric emptying and reduces appetite ³¹.

Secondary effects

• Anti-inflammatory and metabolic improvements: studies report higher adiponectin, lower hs-CRP, and reduced inflammatory markers ¹⁰.
• Reduced "food noise": GLP-1-based drugs including tirzepatide dampen persistent food preoccupation ⁴¹.
• Organ effects in animal models: reduced liver fat and inflammation in MASLD models, kidney protection in an acute kidney injury model, and lung protection in an LPS model ⁴⁴.
• Brain access is limited: direct blood-brain-barrier penetration by tirzepatide is not established; central appetite effects likely occur through accessible regions ⁴⁷.

Weight loss

• In a network meta-analysis of randomized trials, tirzepatide 15 mg produced the largest mean weight reduction among incretin-based agents, about -17.97 percentage points versus placebo ³.
• In a large UK real-world cohort, mean weight loss was -13.5% at 6 months and -17.4% at 12 months ¹⁹.
• Head-to-head evidence found tirzepatide beats semaglutide by -4.28 percentage points (-4.43 kg), with higher odds of 10%, 15%, and 20% losses but more serious adverse events ¹.
• A low-dose cohort found 2.5 mg and 5 mg produced similar 6-month loss (-15.3% vs -16.1%) ¹³.

Glycemic control

• In SURPASS-CN-MONO monotherapy, HbA1c fell about 2.1 percentage points across 5/10/15 mg arms at week 40 versus no change with placebo ⁹.

Body composition

• Network meta-analysis ranks tirzepatide first for fat-mass reduction (-10.70 kg vs placebo) but also notes lean-mass loss (-4.40 kg) ¹⁷.
• The investigational anti-myostatin antibody apitegromab preserved more lean mass in a phase 2 trial when added to tirzepatide ¹⁶.

Cardiovascular, kidney, liver, and sleep outcomes

• SURPASS-CVOT found non-inferiority for major cardiovascular events, and imputed placebo analysis estimated lower events and death ⁷.
• Kidney analyses showed fewer composite kidney events and slower eGFR decline ⁸.
• In obesity-related heart failure with preserved ejection fraction, tirzepatide improved symptoms and 6-minute walk distance in randomized trials ⁶.
• Liver biopsy-based phase 2 data show MASH resolution without fibrosis worsening in 44-62% of participants ¹⁸.
• In OSA with obesity, 10-15 mg weekly reduced apnea-hypopnea index by 25-29 events per hour ³⁴.

Published research protocols use a fixed weekly subcutaneous schedule, not weight-based dosing ⁴. A standard schedule starts at 2.5 mg once weekly for 4 weeks, then escalates by 2.5 mg every 4 weeks through 5, 7.5, 10, 12.5, and 15 mg, pausing at the lowest effective dose ⁴.

Not every trial reaches the maximum dose. In a Japanese cohort, 2.5 mg and 5 mg achieved nearly identical 6-month weight loss, with fewer GI events at 2.5 mg ¹³. Large real-world cohorts also show meaningful weight loss on intermediate doses ¹⁹.

Protocols for adults 65 and older use the same titration with comparable efficacy and safety ¹⁵.

Branded tirzepatide (Mounjaro and Zepbound) ships as a ready-to-inject solution in single-dose prefilled pens or single-dose vials, so no reconstitution is needed for these products ³². Available strengths include 2.5, 5, 7.5, 10, 12.5, and 15 mg per device ³².

Lyophilized tirzepatide powder from unregulated research sources must be reconstituted before research use. Standard peptide handling uses bacteriostatic water as the diluent. Add the diluent slowly down the vial wall and swirl gently. Do not shake or vortex because mechanical agitation can damage the peptide. Use only clear, colorless solution.

Storage:

• Dry lyophilized powder is stored frozen at -20°C for long-term stability, with refrigeration at 2-8°C acceptable short term.
• Reconstituted solution is refrigerated at 2-8°C and used within 28-30 days of first puncture as a sterility precaution.
• Branded pens and vials are refrigerated at 2-8°C and are single-dose devices.

For volumes and dose math, use the interactive reconstitution calculator in this section.

Tirzepatide slows stomach emptying, which changes the absorption timing and completeness of oral medicines ³⁵. Most documented interactions come from this effect or from additive glucose lowering.

• Insulin or sulfonylureas: additive glucose-lowering can cause hypoglycemia. In a type 1 diabetes cohort, total daily insulin fell by about 30 units over 12 months, and abrupt transitions have produced ketoalkalosis ²³.
• Oral contraceptives: delayed gastric emptying can reduce pill absorption. Research protocols use backup non-oral contraception for 4 weeks after starting and after each dose increase ⁴⁸.
• Levothyroxine: stable-dose users can develop a drop in thyroid-stimulating hormone; one study found 29% became suppressed within 4-8 weeks ⁶⁹.
• Warfarin: reduced vitamin K intake and absorption changes have produced supratherapeutic INR and pulmonary hemorrhage in case reports ⁷⁵.
• Lithium: altered absorption and dehydration have produced lithium toxicity requiring hemodialysis in a previously stable patient ⁷⁴.
• Anesthesia and sedation: residual stomach contents despite fasting raise aspiration risk; prescribers and anesthesiologists often adjust holding before procedures ³⁵.
• Other GLP-1 receptor agonists: combining with semaglutide, liraglutide, or dulaglutide duplicates the same mechanism and is not recommended in reimbursement frameworks ³².

Supplement data are limited. A case report linked hypercalcemia to concurrent calcium supplementation ⁸³, and computational screening flagged several herbal candidates as hypothesis-generating only ⁸⁴. Protein and electrolyte monitoring is suggested during large weight loss ⁵³.

No evidence supports classic on/off cycling for receptor desensitization. Longer treatment duration predicts greater weight loss in meta-analysis ². Scheduled gaps are a regain window: in a Japanese cohort under a mandated 68-72 week treatment cap, 95% regained weight within 2 months of stopping ³⁶.

What research and policy describe as cycling usually takes three forms:

• Responder-gated continuation: reimbursement criteria require at least 5% body-weight loss from baseline after one year to continue ³².
• Time-capped treatment: Japan's optimized-use guideline mandates a treatment cap, followed by washout ³⁶.
• Pauses for life events: surgery, pregnancy planning, or access gaps. After any gap of 2 weeks or more, protocols restart at 2.5 mg weekly and re-titrate.

Low-dose maintenance with 2.5-5 mg is a data-supported alternative to full stopping, preserving most efficacy with less drug exposure ¹³.

Tirzepatide is not combined with other incretin-based peptides such as semaglutide, liraglutide, dulaglutide, or cagrilintide because the mechanisms are redundant and regulatory frameworks exclude combination use ³². Dual or triple co-agonists such as CagriSema and retatrutide are alternatives rather than stacking partners ³.

The only evidence-supported additions are non-peptide or investigational:

• Resistance exercise and protein: preserves muscle and aerobic fitness during tirzepatide-induced weight loss ⁵¹.
• Apitegromab: an investigational anti-myostatin antibody that preserved lean mass in a phase 2 trial ¹⁶.

Community protocols sometimes pair tirzepatide with BPC-157 or growth hormone secretagogues for GI tolerance or muscle preservation, but no published evidence supports these combinations.

Tirzepatide is FDA approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management (2023), and Zepbound for obstructive sleep apnea with obesity (2024) ³⁰. It is prescription-only in all jurisdictions.

Reimbursement and access rules vary. Canada recommends public coverage for Zepbound only for adults with BMI 27 or higher plus prediabetes, with continuation tied to at least 5% weight loss after one year ³². Mounjaro is reimbursed for type 2 diabetes at cost parity with semaglutide ³³. Japan requires a 6-month lifestyle intervention before obesity use and caps treatment at 68-72 weeks ³⁶.

Compounded tirzepatide is widely prescribed as a lower-cost alternative. Propensity-matched data found 6-month weight loss statistically equivalent to branded product within a prespecified margin ²⁹. Prescribing without an FDA-approved indication has risen sharply, including people with normal BMI ⁹⁷.

In sports, tirzepatide does not appear on the WADA Prohibited List in the evidence reviewed, and no athlete sanctions are documented.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and reduced appetite. These cluster early in titration, with a median time to onset of 13 days in postmarketing reports ²⁶.

• GI events: mostly mild to moderate and dose dependent ³⁰.
• Serious adverse events: head-to-head pooled evidence found a higher serious-AE rate with tirzepatide versus semaglutide (RR 1.83), while discontinuation rates were similar ¹.
• Ketoacidosis spectrum: starvation ketoacidosis is the strongest postmarketing signal. Cases cluster in unsupervised weight-loss use and very low calorie intake ²⁷.
• Pancreatitis and gallbladder events: pancreatitis is rare, and many cases have gallstone or alcohol confounders ⁶³. Biliary events also appear elevated in pharmacovigilance analyses ⁸².
• Motility problems: severe constipation, gastroparesis, or bowel obstruction occur at roughly 1 per 100 person-years, about 37% higher than with SGLT2 inhibitors ⁶⁰.
• Hair loss: reported, likely a temporary stress-related shedding after rapid weight loss ⁶⁴.
• Lean mass loss: meta-analyses estimate about 4.4 kg lean mass loss, which supports protein and resistance training ¹⁷.
• Aspiration risk: package inserts warn of pulmonary aspiration during anesthesia or deep sedation despite preoperative fasting ³⁵.
• Mood and psychiatric signals: pharmacovigilance reports of depressed mood and suicidal thoughts showed a signal in diabetes cohorts, but the FDA later requested removal of the suicidality warning from Zepbound ⁶⁵.
• Allergic reactions: anaphylaxis confirmed by skin testing has been reported ⁶⁷.
• Acute kidney injury: severe vomiting or diarrhea can cause dehydration-related kidney injury, particularly with diuretics ⁶⁸.

Contraindications include personal or family history of medullary thyroid carcinoma or MEN2, prior serious hypersensitivity, and pregnancy during active weight management ³⁰. Caution is advised with prior pancreatitis, gallbladder disease, severe gastroparesis, or active eating disorders ⁶².